Skip to main content

Parents Appear Receptive to Children Receiving HPV Vaccine at 9 or 10 Years of Age

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 2, 2025.

via HealthDay

MONDAY, June 2, 2025 -- Clinicians consider administration of human papillomavirus (HPV) vaccine as feasible at age 9 to 10 years, and parents appear to be receptive to discussing vaccination at this age, according to a study published online June 2 in Pediatrics.

Caroline K. Tietbohl, Ph.D., from the University of Colorado and Children's Hospital Colorado in Aurora, and colleagues conducted an explanatory sequential mixed-methods study as part of an ongoing randomized trial that compared initiation at ages 9 to 10 years (intervention) versus 11 to 12 years (control) across 17 practices in Colorado (nine intervention) and 16 practices in California (eight intervention). At one month after study initiation, practice clinicians were surveyed, and semistructured interviews were conducted at three months after study initiation.

One-month surveys were completed by 66 and 39 Colorado and California clinicians (92 and 87 percent, respectively); 90 and 77 percent, respectively, were routinely initiating vaccines at age 9 or 10 years. The researchers found that most clinicians reported that vaccination at ages 9 to 10 years was not burdensome; issues were mainly unchanged, including parental concerns and discussion times. According to interviewees, many parents seemed receptive to discussing HPV vaccination at ages 9 to 10 years; pushback often resulted from child expectations for a vaccine-free visit at age 9 years, rather than concerns relating to vaccination. Since sexual activity was not perceived as salient, discussions at ages 9 to 10 years were shorter. The option of spacing out vaccines was preferred by many, with administration of a single vaccine at age 9 years and fewer at age 11 years.

"The results of our prospective trial will determine if initiating vaccination earlier increases vaccination completion rates, especially by age 13 years," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

COVID-19 Tied to Higher Risk for Inflammatory Diseases of the Airways

THURSDAY, Aug. 28, 2025 -- People who have had COVID-19 have an increased risk for developing certain new-onset type 2 inflammatory diseases of the airways, while receipt of a...

Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024

TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...

Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus

TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.